>
Vaxart Inc logo

VXRT - Vaxart Inc Share Price

$5.42 0.4  7.1%

Last Trade - 7:05pm

Sector
Healthcare
Size
Mid Cap
Market Cap £427.6m
Enterprise Value £336.6m
Revenue £2.90m
Position in Universe 3314th / 6852
Bullish
Bearish
Unlock VXRT Revenue
Momentum
Relative Strength (%)
1m -30.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -79.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
9.30 8.90 5.84 4.16 9.86 4.05 26.4 89.5 -15.3%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, VaxartInc revenues decreased 59% to $4M. Net loss increased 73%to $32.2M. Revenues reflect Royalty Income - Businessdecrease of 82% to $886K, Royalty revenue and milestonesdecrease of 33% to $3M, Revenue from customer servicecontracts decrease of 51% to $198K. Higher net lossreflects Interest income decrease of 50% to $75K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for VXRT
Graphical History

Revenue

VXRT Revenue Unlock VXRT Revenue

Net Income

VXRT Net Income Unlock VXRT Revenue

Normalised EPS

VXRT Normalised EPS Unlock VXRT Revenue

PE Ratio Range

VXRT PE Ratio Range Unlock VXRT Revenue

Dividend Yield Range

VXRT Dividend Yield Range Unlock VXRT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
VXRT EPS Forecasts Unlock VXRT Revenue
Profile Summary

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated March 14, 1969
Public Since March 17, 1980
No. of Shareholders: 6,497
No. of Employees: 28
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 117,766,672
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VXRT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VXRT
Upcoming Events for VXRT
Frequently Asked Questions for Vaxart Inc
What is the Vaxart Inc share price?

As of 7:05pm, shares in Vaxart Inc are trading at $5.42, giving the company a market capitalisation of £427.6m. This share price information is delayed by 15 minutes.

How has the Vaxart Inc share price performed this year?

Shares in Vaxart Inc are currently trading at $5.42 and the price has moved by 0.114k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Vaxart Inc price has moved by 40.34% over the past year.

What are the analyst and broker recommendations for Vaxart Inc?

Of the analysts with advisory recommendations for Vaxart Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Vaxart Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Vaxart Inc next release its financial results?

Vaxart Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Vaxart Inc dividend yield?

Vaxart Inc does not currently pay a dividend.

Does Vaxart Inc pay a dividend?

Vaxart Inc does not currently pay a dividend.

When does Vaxart Inc next pay dividends?

Vaxart Inc does not currently pay a dividend.

How do I buy Vaxart Inc shares?

To buy shares in Vaxart Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Vaxart Inc?

Shares in Vaxart Inc are currently trading at $5.42, giving the company a market capitalisation of £427.6m.

Where are Vaxart Inc shares listed? Where are Vaxart Inc shares listed?

Here are the trading details for Vaxart Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: VXRT
What kind of share is Vaxart Inc?

Based on an overall assessment of its quality, value and momentum, Vaxart Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Vaxart Inc share price forecast 2021?

Shares in Vaxart Inc are currently priced at $5.42. At that level they are trading at 0.163% discount to the analyst consensus target price of 0.00.

Analysts covering Vaxart Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.407 for the next financial year.

How can I tell whether the Vaxart Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vaxart Inc. Over the past six months, the relative strength of its shares against the market has been -22.72%. At the current price of $5.42, shares in Vaxart Inc are trading at -32.66% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Vaxart Inc PE Ratio?

We were not able to find PE ratio data for Vaxart Inc.

Who are the key directors of Vaxart Inc?

Vaxart Inc's management team is headed by:

Wouter Latour - CHM
Michael Finney - IND
Sean Tucker - CSO
Margaret Echerd - CAO
Steven Boyd - DRC
Keith Maher - DRC
Todd Davis - IND
Robert Yedid - LED
Andrei Floroiu - CEO
Who are the major shareholders of Vaxart Inc?

Here are the top five shareholders of Vaxart Inc based on the size of their shareholding:

State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 8.02% (9.44m shares)
SPDR S&P Biotech ETF Mutual Fund
Percentage owned: 6.25% (7.36m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 4.38% (5.16m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 3.84% (4.53m shares)
Vanguard Total Stock Market Index Fund Mutual Fund
Percentage owned: 2.51% (2.95m shares)
Similar to VXRT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.